NNNN

Anbio Biotechnology

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Advanced Metrics

NNNN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$23.54M	$6.71M	$8.19M	$8.65M
Cost of Revenue	$10.98M	$3.35M	$2.30M	$1.10M
Gross Profit	$12.56M	$3.36M	$5.89M	$7.54M
Research & Development	$200.00K	$134.70K	$454.23K	$201.31K
Selling, General & Admin	$2.17M	$1.27M	$3.44M	$1.57M
Operating Expenses	$2.37M	$1.40M	$3.89M	$1.78M
Operating Income	$10.20M	$1.96M	$2.00M	$5.77M
EBITDA	$10.03M	$1.97M	$2.00M	$5.77M
Pretax Income	$10.01M	$2.25M	$2.37M	$6.40M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	$10.01M	$2.25M	$2.37M	$6.40M
Diluted EPS	0.07	0.01	0.05	—
Diluted Shares	143.89M	187.78M	43.89M	—

NNNN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.10M	$9.69M	$11.76M	$7.77M
Receivables	$3.58K	$1.88M	$1.06M	$3.66M
Inventory	$353.87K	$0.00	—	—
Current Assets	$13.94M	$15.75M	$18.53M	$30.24M
Total Assets	$13.96M	$15.81M	$18.92M	$30.24M
Current Liabilities	$1.41M	$993.06K	$1.73M	$87.84K
Total Liabilities	$1.41M	$993.06K	$1.73M	$87.84K
Retained Earnings	$12.55M	$14.80M	$17.17M	$23.58M
Shareholders' Equity	$12.55M	$14.82M	$17.19M	$30.16M
Working Capital	$12.53M	$14.76M	$16.80M	$30.16M

NNNN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$4.45M	$898.37K	$2.08M	-$6.74M
Free Cash Flow	$4.45M	$898.37K	$2.08M	-$6.74M
Depreciation & Amortisation	$6.25K	$12.06K	$0.00	—
Investing Cash Flow	-$1.53M	$1.73M	$337.10K	-$4.20M
Financing Cash Flow	$0.00	-$42.84K	-$344.61K	$6.95M
Net Change in Cash	$2.92M	$2.59M	$2.07M	-$3.99M

NNNN Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	$11.76M	$5.35M	$7.77M
Receivables	$1.06M	$3.72M	$3.66M
Current Assets	$18.53M	$27.68M	$30.24M
Total Assets	$18.92M	$27.68M	$30.24M
Current Liabilities	$1.73M	$131.13K	$87.84K
Total Liabilities	$1.73M	$131.13K	$87.84K
Retained Earnings	$17.17M	$20.97M	$23.58M
Shareholders' Equity	$17.19M	$27.55M	$30.16M
Working Capital	$16.80M	$27.55M	$30.16M

Anbio Biotechnology is a Chinese biotech company specializing in in-vitro diagnostic products and rapid testing solutions for medical applications.